Kotz R, Plattner E, Ramach W, Flener R, Bodo G
Arzneimittelforschung. 1982;32(4):446-8.
In eight patients with osteosarcoma we conducted a controlled tolerance study with human lymphoblast interferon. Interferon was applied for 12 months and the control period after stopping interferon has lasted 12-42 months up to now. 4 out of 8 patients who received interferon did not show any adverse reaction concerning clinical and laboratory tests during the course of a 1-year application and during the follow-up period, resp. Only reversible thrombopenias and an increase in the alpha 2-globulins fraction were observed in the interferon and in the control group, resp. All of the 8 patients have up to now survived tumor-free.
我们对8例骨肉瘤患者进行了人淋巴细胞干扰素的耐受性对照研究。干扰素应用12个月,截至目前,停止使用干扰素后的对照期已持续12 - 42个月。8例接受干扰素治疗的患者中,分别有4例在1年的用药过程及随访期间,临床和实验室检查均未出现任何不良反应。分别在干扰素组和对照组中观察到了仅为可逆性血小板减少症以及α2球蛋白组分增加的情况。截至目前,所有8例患者均无瘤存活。